Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975 on ClinicalTrials.gov · last registry update 2025-11-25
Recruiting now, toward 420 participants. Due to report 30 June 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in body weight from baseline after 52 weeks (W) of treatment. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Gan & Lee Pharmaceuticals.
- Sponsor type
- Industry
- Enrollment
- 420
- Started
- 2025-09-23
- Primary completion
- 2027-06-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage change in body weight from baseline after 52 weeks (W) of treatment.
Conditions studied
Obesity/Overweight in Adult
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.